Diabetes mellitus: Exploring the challenges in the drug development process
Authors:
Open Access
- 1 January 2012
- journal article
- drug development
- Published by Medknow in Perspectives in Clinical Research
- Vol. 3 (3) , 109-12
Abstract
Diabetes mellitus has reached epidemic proportions and continues to be a major burden on society globally. The International Diabetes Federation (IDF) estimated the global burden of diabetes to be 366 million in 2011 and predicted that by 2030 this will have risen to 552 million. In spite of newer and effective treatment options, newer delivery and diagnostic devices, stricter glycaemic targets, better treatment guidelines and increased awareness of the disease, baseline glycosylated hemoglobin remains relatively high in subjects diagnosed and treated with type 2 diabetes. The search continues for an ideal anti diabetic drug that will not only normalize blood glucose but also provide beta cell rest and possibly restoration of beta cell function. The development of anti diabetic drugs is riddled with fundamental challenges. The concept of beta cell rest and restoration is yet to be completely understood and proven on a long term. The ideal therapeutic approach to treating type 2 diabetes is not yet determined. Our understanding of drug safety in early clinical development is primarily limited to "Type A" reactions. Until marketing authorization most drugs are approved based on the principle of confirming non-inferiority with an existing gold standard or determining superiority to a placebo. The need to obtain robust pharmaco-economic data prior to marketing authorization in order to determine appropriate pricing of a new drug remains a major challenge. The present review outlines some of the challenges in drug development of anti-diabetic drugs citing examples of pulmonary insulin, insulin analogues, thiazolidinediones and the GLP1 analogues.Keywords
This publication has 16 references indexed in Scilit:
- The pharmacological treatment of obesity: Past, present and futureOrvosi Hetilap, 2012
- Executive Summary: Standards of Medical Care in Diabetes—2012Diabetes Care, 2011
- Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and BenefitsDiabetes Care, 2010
- Diabetes Treatment by Inhalation of Insulin – Shine and Decline of a Novel Type of Therapy2010
- Three-Year Efficacy of Complex Insulin Regimens in Type 2 DiabetesNew England Journal of Medicine, 2009
- Beta cell mass in diabetes: a realistic therapeutic target?Diabetologia, 2008
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetesDiabetes, Obesity and Metabolism, 2006
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993